Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies.
Over the past decades, Positron Emission Tomography has opened a new field of imaging. Nowadays, this technique is being used for diagnosing, staging disease as well as for prognostic stratification and monitoring therapy. In this respect, [18F]fluorodeoxyglucose (FdGlc) is by far the most commonly used PET agent. Many factors have been identified being responsible for a high uptake of this agent in malignancy. However, additional factors such as tumour treatment may interfere with the uptake mechanism. Knowledge of all these factors is a prerequisite for an optimal interpretation of PET studies and, consequently, for a reliable judgement of tumour status. In this article, a review is given of the factors influencing FdGlc uptake and the implications for clinical studies.
Pauwels
E K
EK
Leiden University Medical Centre, Division of Nuclear Medicine, The Netherlands. pauwels@mail.medfac.leidenuniv.nl
Sturm
E J
EJ
Bombardieri
E
E
Cleton
F J
FJ
Stokkel
M P
MP
D002952:Citric Acid Cycle; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism*; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006019:Glycolysis; D006593:Hexokinase / Q000378:metabolism; D006801:Humans; D008928:Mitochondria / Q000378:metabolism; D009004:Monosaccharide Transport Proteins / Q000378:metabolism; D009369:Neoplasms / Q000378:metabolism; D019275:Radiopharmaceuticals / Q000378:metabolism*; D014055:Tomography, Emission-Computed / Q000379:methods; D015854:Up-Regulation
D009004:Monosaccharide Transport Proteins; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D006593:Hexokinase